Draft guidance released for 2028 cycle of Medicare drug price negotiations
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation program. Policies on incorporating drugs payable under Medicare Part B or covered under Part D are included in the guidance. It also describes procedures that may apply to drug manufacturers, Part D plan sponsors, Medicare Advantage organizations, pharmacies, mail order services and other Part D drug-dispensing entities, as well as hospitals, physicians and other providers that furnish or administer drugs payable under Part B. CMS is accepting comments on the draft guidance until Sept. 18.
Related News Articles
Headline
The U.S. District Court for the Eastern District of Pennsylvania Aug. 5 granted a motion for the AHA and the Hospital and Healthsystem Association of…
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that would increase Medicare rates by a net 2.3% in fiscal year 2027, compared with…
Headline
The Centers for Medicare & Medicaid Services July 27 released its Contract Year 2025 Part C and Part D Program Audit and Enforcement Report, outlining key…
Headline
The Centers for Medicare & Medicaid Services has released an updated FAQ on Protecting Access to Medicare Act private payer data reporting. The deadline is…
Headline
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible…
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…
